^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-514
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
CCR8 inhibitor
Related drugs:
over1year
First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors (ESMO 2023)
In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort. Enrollment initiated in November 2021, with 30 patients enrolled as of April 2023.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
budigalimab (ABBV-181) • ABBV-514
over3years
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab (clinicaltrials.gov)
P1, N=136, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514
over3years
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab (clinicaltrials.gov)
P1, N=136, Not yet recruiting, AbbVie
Clinical • New P1 trial • Adverse events • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514
Share via
